Cullinan Associates’s Medtronic MDT Stock Holding History

Cullinan Associates’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.74M	Sell	43,117 -175	-0.4%	-$16.8K	0.3%	67
2025 Q4	$4.16M	Sell	43,292 -473	-1%	-$45.9K	0.28%	70
2025 Q3	$4.17M	Sell	43,765 -5,341	-11%	-$491K	0.27%	68
2025 Q2	$4.28M	Buy	49,106 +2,780	+6%	+$236K	0.28%	70
2025 Q1	$4.16M	Sell	46,326 -1,860	-4%	-$166K	0.29%	74
2024 Q4	$3.85M	Sell	48,186 -8,378	-15%	-$725K	0.25%	80
2024 Q3	$5.16M	Sell	56,564 -2,047	-3%	-$172K	0.29%	69
2024 Q2	$4.61M	Sell	58,611 -9,197	-14%	-$754K	0.26%	77
2024 Q1	$5.91M	Sell	67,808 -10,440	-13%	-$891K	0.33%	63
2023 Q4	$6.45M	Sell	78,248 -48,917	-38%	-$3.73M	0.36%	63
2023 Q3	$9.96M	Sell	127,165 -9,150	-7%	-$766K	0.58%	43
2023 Q2	$12M	Sell	136,315 -8,085	-6%	-$696K	0.66%	38
2023 Q1	$11.6M	Buy	144,400 +45,256	+46%	+$3.69M	0.68%	41
2022 Q4	$7.71M	Sell	99,144 -44,119	-31%	-$3.58M	0.43%	53
2022 Q3	$11.6M	Buy	143,263 +3,909	+3%	+$351K	0.73%	38
2022 Q2	$12.5M	Buy	139,354 +25,402	+22%	+$2.57M	0.76%	37
2022 Q1	$12.6M	Buy	113,952 +750	+0.7%	+$79.2K	0.66%	45
2021 Q4	$11.7M	Buy	113,202 +1,186	+1%	+$137K	0.6%	48
2021 Q3	$14M	Buy	112,016 +4,034	+4%	+$522K	0.78%	33
2021 Q2	$13.4M	Buy	107,982 +16,450	+18%	+$2.07M	0.75%	38
2021 Q1	$10.8M	Sell	91,532 -155	-0.2%	-$18.2K	0.62%	41
2020 Q4	$10.7M	Buy	91,687 +1,455	+2%	+$160K	0.64%	38
2020 Q3	$9.38M	Buy	90,232 +1,143	+1%	+$115K	0.6%	40
2020 Q2	$8.17M	Buy	89,089 +550	+0.6%	+$52.7K	0.57%	39
2020 Q1	$7.98M	Sell	88,539 -1,768	-2%	-$188K	0.65%	37
2019 Q4	$10.2M	Buy	90,307 +1,855	+2%	+$204K	0.68%	36
2019 Q3	$9.61M	Sell	88,452 -4,089	-4%	-$427K	0.68%	38
2019 Q2	$9.01M	Buy	92,541 +805	+0.9%	+$73.5K	0.65%	41
2019 Q1	$8.36M	Sell	91,736 -1,265	-1%	-$113K	0.63%	45
2018 Q4	$8.46M	Sell	93,001 -83	-0.1%	-$7.76K	0.7%	35
2018 Q3	$9.16M	Sell	93,084 -7,160	-7%	-$662K	0.66%	36
2018 Q2	$8.58M	Sell	100,244 -3,331	-3%	-$278K	0.66%	39
2018 Q1	$8.31M	Buy	103,575 +1,959	+2%	+$162K	0.63%	37
2017 Q4	$8.21M	Sell	101,616 -1,970	-2%	-$158K	0.6%	39
2017 Q3	$8.06M	Sell	103,586 -2,466	-2%	-$205K	0.62%	45
2017 Q2	$9.41M	Sell	106,052 -121	-0.1%	-$10.2K	0.73%	40
2017 Q1	$8.55M	Sell	106,173 -4,300	-4%	-$336K	0.7%	39
2016 Q4	$7.87M	Buy	110,473 +1,777	+2%	+$140K	0.67%	40
2016 Q3	$9.39M	Sell	108,696 -5,814	-5%	-$507K	0.8%	29
2016 Q2	$9.94M	Sell	114,510 -67	-0.1%	-$5.42K	0.81%	29
2016 Q1	$8.59M	Sell	114,577 -1,760	-2%	-$133K	0.73%	33
2015 Q4	$8.95M	Buy	116,337 +19,636	+20%	+$1.48M	0.78%	33
2015 Q3	$6.47M	Buy	96,701 +42,733	+79%	+$3.15M	0.59%	44
2015 Q2	$4M	Buy	53,968 +11,920	+28%	+$911K	0.33%	72
2015 Q1	$3.28M	Sell	42,048 -40,834	-49%	-$3.09M	0.25%	85
2014 Q4	$5.98M	Sell	82,882 -24,400	-23%	-$1.69M	0.63%	28
2014 Q3	$6.65M	Buy	107,282 +160	+0.1%	+$10.2K	0.76%	28
2014 Q2	$5.51M	Sell	107,122 -10,216	-9%	-$621K	0.9%	13
2014 Q1	$7.22M	Buy	117,338 +2,415	+2%	+$141K	0.82%	24
2013 Q4	$6.59M	Sell	114,923 -23,850	-17%	-$1.35M	0.76%	24
2013 Q3	$7.39M	Sell	138,773 -3,499	-2%	-$188K	0.99%	16
2013 Q2	$7.32M	Buy	+142,272	New	+$7.03M	0.99%	13

Other funds holding MDT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cullinan Associates's MDT Position: Q1 2026 in Review

Cullinan Associates reduced its Medtronic (MDT) stake by 0.4% in Q1 2026, selling an estimated $16.8K and leaving 43,117 shares worth $3.74M. The position accounts for 0.3% of the portfolio, ranked #67.

Cullinan Associates first reported a position in MDT in Q2 2013 and has held it in 52 quarters since. The position peaked at $14M in Q3 2021. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

Cullinan Associates held 43,117 shares of Medtronic worth $3.74M as of Q1 2026.
Cullinan Associates sold 175 Medtronic shares in Q1 2026, an estimated $16.8K.
Medtronic made up 0.3% of Cullinan Associates's portfolio in Q1 2026, its #67 holding.
Cullinan Associates first reported a position in Medtronic in Q2 2013 and has held it in 52 quarters since.
Cullinan Associates's Medtronic position peaked at $14M in Q3 2021.
2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.